Dustin S Sjuts is President of Revance Therapeutics, Inc.. Currently has a direct ownership of 167,550 shares of RVNC, which is worth approximately $430,603. The most recent transaction as insider was on Mar 18, 2024, when has been sold 9,211 shares (Common Stock) at a price of $5.04 per share, resulting in proceeds of $46,423. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 168K
0% 3M change
6.48% 12M change
Total Value Held $430,603

Dustin S Sjuts Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 18 2024
SELL
Open market or private sale
$46,423 $5.04 p/Share
9,211 Reduced 5.21%
167,550 Common Stock
Mar 15 2024
SELL
Payment of exercise price or tax liability
$15,725 $5.3 p/Share
2,967 Reduced 1.65%
176,761 Common Stock
Feb 29 2024
BUY
Grant, award, or other acquisition
-
22,110 Added 10.95%
179,728 Common Stock
Dec 31 2023
BUY
Grant, award, or other acquisition
$1,972 $7.47 p/Share
264 Added 0.17%
157,618 Common Stock
Dec 15 2023
SELL
Payment of exercise price or tax liability
$38,072 $8.08 p/Share
4,712 Reduced 2.91%
157,354 Common Stock
Aug 11 2023
SELL
Payment of exercise price or tax liability
$168,317 $18.91 p/Share
8,901 Reduced 5.21%
162,066 Common Stock
Aug 11 2023
BUY
Grant, award, or other acquisition
-
22,620 Added 11.68%
170,967 Common Stock
Jun 30 2023
BUY
Grant, award, or other acquisition
$15,610 $15.61 p/Share
1,000 Added 0.67%
148,347 Common Stock
Jun 09 2023
SELL
Open market or private sale
$154,100 $30.82 p/Share
5,000 Reduced 3.28%
147,347 Common Stock
May 15 2023
SELL
Open market or private sale
$726,068 $34.55 p/Share
21,015 Reduced 12.12%
152,347 Common Stock
Mar 15 2023
SELL
Payment of exercise price or tax liability
$90,938 $30.65 p/Share
2,967 Reduced 2.39%
120,967 Common Stock
Mar 09 2023
SELL
Open market or private sale
$679,437 $31.59 p/Share
21,508 Reduced 14.79%
123,934 Common Stock
Feb 15 2023
SELL
Payment of exercise price or tax liability
$91,858 $33.21 p/Share
2,766 Reduced 2.89%
93,046 Common Stock
Dec 31 2022
BUY
Grant, award, or other acquisition
$7,368 $12.18 p/Share
605 Added 0.63%
95,812 Common Stock
Dec 15 2022
SELL
Payment of exercise price or tax liability
$62,694 $21.5 p/Share
2,916 Reduced 2.97%
95,207 Common Stock
Sep 22 2022
BUY
Grant, award, or other acquisition
-
52,396 Added 26.48%
145,442 Common Stock
Jun 30 2022
BUY
Grant, award, or other acquisition
$11,750 $11.75 p/Share
1,000 Added 1.01%
98,123 Common Stock
Mar 15 2022
SELL
Payment of exercise price or tax liability
$28,975 $15.79 p/Share
1,835 Reduced 1.85%
97,123 Common Stock
Feb 15 2022
SELL
Payment of exercise price or tax liability
$32,427 $13.35 p/Share
2,429 Reduced 2.4%
98,958 Common Stock
Feb 02 2022
BUY
Grant, award, or other acquisition
-
52,395 Added 23.21%
173,362 Common Stock
Dec 15 2021
SELL
Payment of exercise price or tax liability
$8,167 $15.92 p/Share
513 Reduced 0.5%
101,387 Common Stock
Nov 09 2021
BUY
Grant, award, or other acquisition
-
35,920 Added 26.06%
101,900 Common Stock
Jun 30 2021
BUY
Other acquisition or disposition
$21,247 $24.09 p/Share
882 Added 1.32%
65,980 Common Stock
Apr 15 2021
SELL
Payment of exercise price or tax liability
$11,574 $28.16 p/Share
411 Reduced 0.63%
65,098 Common Stock
Feb 15 2021
SELL
Payment of exercise price or tax liability
$69,818 $28.97 p/Share
2,410 Reduced 3.55%
65,509 Common Stock
DSS

Dustin S Sjuts

President
Nashville, TN

Track Institutional and Insider Activities on RVNC

Follow Revance Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVNC shares.

Notify only if
Any

Insider Trading

Get notified when an Revance Therapeutics, Inc. insider buys or sells RVNC shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Revance Therapeutics, Inc.

Track Activities on RVNC